Amgen’s anticompetitive harms 'continue to deepen,' Regeneron says in amended US complaint over Praluent
( August 29, 2023, 21:33 GMT | Official Statement) -- MLex Summary: Amgen has made it "economically unfeasible" to sell a drug benefiting thousands of patients who suffer from high cholesterol, and anticompetitive content "described in black and white" in the company's documents will find additional support in forthcoming discovery, Regeneron told a Delaware federal court in an amended complaint. "Significant, ongoing developments since Regeneron initiated this lawsuit in May of 2022 serve to fully confirm the details and extent of Amgen’s anticompetitive scheme and the harm it is causing," Regeneron said.See document below....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.